THTomasz Hryniewiecki

Tomasz Hryniewiecki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tomasz Hryniewiecki has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex-specific patterns of valvulo-aortopathy in bicuspid aortic valve according to the international consensus framework: insights from the RE-BAV registry

    by Edyta Płońska-Gościniak, Wojciech Kosmala, Jerzy Pacholewicz, Celina Wojciechowska, Ilona Kowalik, Bożena Sobkowicz, Tomasz Hirnle, Andrzej Tomaszewski, Beata Zaborska, Maria Binkiewicz-Orluk, et al.

    Aims: To characterize sex-specific patterns of bicuspid aortic valve (BAV) valvulo-aortopathy using consensus phenotyping and to assess how aortic normalization strategies influence sex-related differences in aortic dimensions. Methods and results: We analysed 808 adults with BAV (mean age 49.9 ± 17.5 years; 588 men) from the RE-BAV registry. Valve morphology, aortopathy phenotypes, and clinical valvulo-aortopathy categories were classified according to consensus definitions. Typical and uncomplicated forms were additionally analysed together as a non-complex category. Proximal aortic dimensions were defined as the aortic root and ascending aorta. Valve morphology distribution did not differ by sex. Although the prevalence of aortic dilatation was similar, phenotype distribution differed: women more frequently exhibited the extended phenotype (34.7% vs. 23.3%, P = 0.001), whereas the root phenotype was more common in men (15.1% vs. 7.8%, P = 0.006). Moderate-to-severe aortic regurgitation was more prevalent in men (50.3% vs. 29.1%, P < 0.001). Sex differences in proximal aortic dimensions varied by normalization strategy. For the ascending aorta, indexing to body surface area yielded larger values in women (21.1 ± 4.0 vs. 20.0 ± 4.0 mm/m², P = 0.001), whereas diameter/height showed no sex-related difference at this level. Conversely, the cross-sectional area-to-height ratio remained higher in men across proximal segments, most prominently at the sinuses of Valsalva (6.9 ± 2.0 vs. 5.6 ± 1.6 cm²/m, P < 0.001). Age was independently associated with larger proximal aortic dimensions across all strategies. Conclusion: Sex-related differences in BAV involved aortopathy phenotype, aortic regurgitation burden, and proximal aortic dimensions. Interpretation of proximal aortic dimensions depended on the normalization strategy used, indicating that indexing methods should not be treated as interchangeable.

  • Open Access

    Clinical Efficacy of Canrenone in Restoring Sinus Rhythm in Patients With Atrial Fibrillation—A Pilot, Randomized, Double-Blind Study

    by Rafał Dąbrowski, Agnieszka Segiet-Święcicka, Stefan Sawicki, Ilona Kowalik, Krzysztof Jaworski, Michał Farkowski, Agata Kubaszek-Kornatowska, Piotr Michałek, Mirosław Dłużniewski, Hanna Szwed, et al.

    Background and aims: Renin-angiotensin-aldosterone system (RAAS) inhibition is an upstream therapy for managing atrial fibrillation (AF). Of all RAAS-inhibiting agents, only canrenone in the form of potassium canrenoate, a specific inhibitor of mineralocorticoid receptors, is administered intravenously. We evaluated the clinical efficacy of intravenous potassium canrenoate in restoring sinus rhythm in patients with paroxysmal AF episodes. Methods: This double-center, randomized, double-blind study comprised 52 patients with AF (lasting P = .477), respectively. Adverse events were observed in 2 (7.4%) and 0 (0.0%) patients in the placebo and canrenone arms, respectively ( P = .170). Conclusions: Intravenous canrenone is not effective in the sinus rhythm restoration among the patients with paroxysmal AF. ClinicalTrials.gov. NCT03536806

  • Open Access

    Preliminary results from the Polish Infective Endocarditis Registry (POL-ENDO): Time to change clinical practice?

    by Jakub W Orzech, Karina Zatorska, Maciej Grabowski, Małgorzata Miłkowska, Maria Jaworska-Wilczyńska, Ilona Kowalik, Tomasz Kukulski, Maciej Lesiak, Andrzej Surdacki, Tomasz Hryniewiecki


  • Open Access

    The Need to Implement Health Technology Assessment in Polish Hospitals—A Survey of 50 Hospital Managers

    by Michał M. Farkowski, Krzysztof Lach, Malwina Pietrzyk, Ewelina Baryla-Zapala, Małgorzata Gałązka-Sobotka, Iwona Kowalska-Bobko, Cezary Kępka, Tomasz Hryniewiecki

    Hospital-based health technology assessment (HB-HTA) is a scientific approach to inform decisions on investments in health technologies across multiple medical specialties at a hospital level. HB-HTA is not currently practiced in Poland. This study aimed to assess the need for HTA in Polish hospitals, including perceived benefits and challenges of adoption of HB-HTA in Poland, expected demand for training in HB-HTA, and perception of incentives to foster HB-HTA adoption. Study data were gathered using the computer-assisted telephone interview (CATI) technique. Between June and August 2021, 50 interviews were conducted: 52% of respondents had over 10 years of experience, and 40% comprised the highest degree reference hospitals. A high or moderate need for HB-HTA was reported by 86% of managers. The ability to indicate valuable and affordable medical technologies was the main reported benefit of HB-HTA (90%). The main obstacle to the adoption of HB-HTA was the shortage of competent staff (84%). The most important incentives to adopt HB-HTA were free training and premium financing from the National Health Fund. There is a clear need for HB-HTA in Polish hospitals despite some important obstacles.


  • Open Access

    The First Case of Granulicatella adiacens Identified from a Resected Heart Valve by Next Generation Sequencing (NGS) in Poland

    by Anna Podgórska, Maria Kordybach-Prokopiuk, Maria Jaworska-Wilczyńska, Piotr Hoffman, Katarzyna Biernacka, Krzysztof Kuśmierski, Robert Kuthan, Tomasz Hryniewiecki, Anna Lutyńska

    In this report, we describe the course and successful treatment of a case of complicated infective endocarditis (IE). A patient presented with a high-grade, irregular fever with chills lasting at least 2 months along with dyspnoea, chest pain, fatigue, weight loss, and night sweats during the previous 3 months. As well as cardiac congenital disorders, he was found to have Granulicatella adiacens infective aortic valve endocarditis, presumably transmitted from the oral cavity niche. Validated metagenomic 16S rDNA next generation sequencing was used to perform taxonomic identification, allowing for specific adequate antibiotic therapy instead of empiric therapy. This paper highlights the critical role of rapid taxonomic identification of nutritionally variant streptococci and the benefit of proper IE treatment in avoiding relapses or fatal complications.


  • Open Access

    The First Case of Granulicatella adiacens Identified from a Resected Heart Valve by Next Generation Sequencing (NGS) in Poland

    by Anna Podgórska, Maria Kordybach-Prokopiuk, Maria Jaworska-Wilczyńska, Piotr Hoffman, Katarzyna Biernacka, Krzysztof Kuśmierski, Robert Kuthan, Tomasz Hryniewiecki, Anna Lutyńska

    In this report, we describe the course and successful treatment of complicated infective endocarditis (IE). A patient presented with a high-grade irregular fever with chills lasting at least 2 months, dyspnoea, chest pain, fatigue, weight loss, and night sweats during the previous 3 months. Above cardiac congenital disorders, he was found to have Granulicatella adiacens infective aortic valve endocarditis, presumably transmitted from the oral cavity niche. Validated metagenomic 16S rDNA next generation sequencing was used to perform taxonomic identification, allowing for specific adequate antibiotic therapy instead of empiric therapy. This paper highlights the critical role of rapid taxonomic identification of nutritionally variant streptococci crucial and the benefit of proper IE treatment to avoid relapses or fatal complications.


  • Blood Pressure and Arterial Stiffness in Association With Aircraft Noise Exposure:Long-Term Observation and Potential Effect of COVID-19 Lockdown

    by Wiktoria Wojciechowska, Andrzej Januszewicz, Tomasz Drożdż, Marta Rojek, Justyna Bączalska, Michał Terlecki, Karol Kurasz, Agnieszka Olszanecka, Mikołaj Smólski, Aleksander Prejbisz, et al.

    In a cross-sectional analysis of a case-control study in 2015, we revealed the association between increased arterial stiffness (pulse wave velocity) and aircraft noise exposure. In June 2020, we evaluated the long-term effects, and the impact of a sudden decline in noise exposure during the coronavirus disease 2019 (COVID-19) lockdown, on blood pressure and pulse wave velocity, comparing 74 participants exposed to long-term day-evening-night aircraft noise level > 60 dB and 75 unexposed individuals. During the 5-year follow-up, the prevalence of hypertension increased in the exposed (42% versus 59%, P =0.048) but not in the unexposed group. The decline in noise exposure since April 2020 was accompanied with a significant decrease of noise annoyance, 24-hour systolic (121.2 versus 117.9 mm Hg; P =0.034) and diastolic (75.1 versus 72.0 mm Hg; P =0.003) blood pressure, and pulse wave velocity (10.2 versus 8.8 m/s; P =0.001) in the exposed group. Less profound decreases of these parameters were noticed in the unexposed group. Significant between group differences were observed for declines in office and night-time diastolic blood pressure and pulse wave velocity. Importantly, the difference in the reduction of pulse wave velocity between exposed and unexposed participants remained significant after adjustment for covariates (−1.49 versus −0.35 m/s; P =0.017). The observed difference in insomnia prevalence between exposed and unexposed individuals at baseline was no more significant at follow-up. Thus, long-term aircraft noise exposure may increase the prevalence of hypertension and accelerate arterial stiffening. However, even short-term noise reduction, as experienced during the COVID-19 lockdown, may reverse those unfavorable effects.


  • The role of cardiac computed tomography in the diagnosis of prosthetic valve endocarditis – A comparison with transthoracic and transesophageal echocardiography and intra-operative findings

    by Ilona Michałowska, Patrycjusz Stokłosa, Małgorzata Miłkowska, Dariusz Zakrzewski, Małgorzata Nieznańska, Paweł Kwiatek, Sylwia Lewandowska, Krzysztof Kuśmierski, Piotr Kołsut, Mariusz Kuśmierczyk, et al.


  • Open Access

    Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial)

    by Rafał Dąbrowski, Paweł Syska, Justyna Mączyńska, Michał Farkowski, Stefan Sawicki, Agata Kubaszek-Kornatowska, Piotr Michałek, Ilona Kowalik, Hanna Szwed, Tomasz Hryniewiecki

    Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal disturbances, atrial volume overload). There is still the need for an effective and safe approach to increase AF cardioversion efficacy. This randomized, double-blind, placebo-controlled, superiority clinical study is performed in patients with AF in order to evaluate the clinical efficacy of intravenous canrenone in sinus rhythm restoration. Methods: Eighty eligible patients with an episode of AF lasting less than 48 h are randomized in a 1:1 ratio to receive canrenone or placebo. Patients randomized to a treatment intervention are receiving canrenone intravenously at a dose of 200 mg within 2–3 min. Subjects assigned to a control group obtain the same volume of 0.9% saline within the same time. The primary endpoint includes return of sinus rhythm documented in the electrocardiogram within 2 h after drug or placebo administration. Other endpoints and safety outcomes analyses, due to expected lack of statistical power, are exploratory. Discussion: Current evidence supports renin–angiotensin–aldosterone system (RAAS) inhibition as an upstream therapy in AF management. Excess aldosterone secretion results in proarrhythmic effects. Among the RAAS inhibitors, only canrenone is administered intravenously. Canrenone additionally increases the plasma level of potassium, lowers blood pressure and reduces preload. It has been already used in primary and secondary hyperaldosteronism in the course of chronic liver dysfunction and in heart failure. Trial registration: ClinicalTrials.gov, NCT03536806. Registered on 25 May 2018.


  • Open Access

    Association of Inadequately Low Left Ventricular Mass with Enhanced Myocardial Contractility in Severe Degenerative Aortic Stenosis

    by Bernadeta Chyrchel, Dorota Długosz, Klaudiusz Bolt, Olga Kruszelnicka, Artur Dziewierz, Jolanta Świerszcz, Ewa Wieczorek-Surdacka, Tomasz Hryniewiecki, Andrzej Surdacki

    Background: Left ventricular hypertrophy (LVH), traditionally considered an adaptive mechanism that is aimed at the maintenance of LV systolic function, is absent in 10%–35% of patients with severe aortic stenosis (AS). Our aim was to estimate the clinical and hemodynamic characteristics in patients with severe AS and absent LVH, or inadequately low LV mass (i-lowLVM) relative to an individual hemodynamic load. Methods: We retrospectively analyzed in-hospital records of 100 patients with pure severe degenerative AS, preserved LV systolic function and without relevant coexistent diseases, except for well-controlled hypertension or diabetes. Results: Clinical characteristics were similar in patients with and without LVH, as well as those with and without i-lowLVM, except for slightly lower GFR at i-lowLVM. When compared to their counterparts, subjects without LVH or with i-lowLVM had smaller LV cavities, decreased LV wall thicknesses and higher EF. There were no significant differences in stenosis severity and indices of afterload (valvulo-arterial impedance and circumferential end-systolic LV wall stress), according to the presence or absence of either LVH or i-lowLVM. However, LV fractional shortening at the midwall level was elevated only in patients with i-lowLVM, but not in those without LVH, compared to the remainder (15.8 ± 3.3 vs. 12.9 ± 3.2%, p < 0.001 for those with and without i-lowLVM, respectively; 13.7 ± 3.7 vs. 13.8 ± 3.6% for LVH presence and absence, p = 0.9). Conclusions: Inadequately low LVM relative to the individual hemodynamic load could potentially reflect a different mode of the LV response to severe AS, associated with enhanced load-independent LV systolic performance, i.e., better LV contractility. If confirmed in a large series of patients, our small preliminary study may add to the possible mechanisms of a previously reported counterintuitive tendency of a lower, not higher, risk of adverse outcome in patients with low LV mass despite severe AS. Prospective studies are warranted, in order to determine a potential utility of LVM inadequacy in the risk stratification of patients with AS.